Page last updated: 2024-12-11

cotylenin a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cotylenin A: induces differentiation in murine and human myeloid leukemia cells; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5458687
MeSH IDM0383513

Synonyms (12)

Synonym
unii-o6g9s48jrx
nsc 319518
o6g9s48jrx ,
dicyclopenta(a,d)cyclooctene-1,5-diol, 1,2,3,3a,4,5,6,8,9,9a-decahydro-1-(methoxymethyl)-4-methyl-7-(1-methylethyl)-6-(((2s,3s,4as,5r,7s,8r,8ar)-tetrahydro-8-hydroxy-5-(methoxymethyl)-3-methyl-3-((2s)-oxiranyl)-7h-2,4a-epoxy-5h-pyrano(3,4-b)-1,4-dioxin-7-
nsc-319518
12708-37-1
nsc319518 ,
cotylenin a
dicyclopenta[a,d]cyclooctene-1,5-diol, 1,2,3,3a,4,5,6,8,9,9a-decahydro-1-(methoxymethyl)-4-methyl-7-(1-methylethyl)-6-[[(2s,3s,4as,5r,7s,8r,8ar)-tetrahydro-8-hydroxy-5-(methoxymethyl)-3-methyl-3-[(2s)-oxiranyl]-7h-2,4a-epoxy-5h-pyrano[3,4-b]-1,4-dioxin-7-
(1r,2e,4r,7s,8r,9r,10r)-10-[[(1r,4s,9s)-5-hydroxy-2-(methoxymethyl)-9-methyl-9-(oxiran-2-yl)-3,7,10,11-tetraoxatricyclo[6.2.1.01,6]undecan-4-yl]oxy]-4-(methoxymethyl)-1,8-dimethyl-12-propan-2-yltricyclo[9.3.0.03,7]tetradeca-2,11-diene-4,9-diol
.alpha.-d-xylo-hexopyranosid-4-ulose, 1,2,4,5,6,6a,7,8,9,10a-decahydro-5,9-dihydroxy-9-(methoxymethyl)-6,10a-dimethyl-3-(1-methylethyl)dicyclopenta(a,d)cycloocten-4-yl 6-o-methyl-, cyclic 2-hydroxy-1-methyl-1-oxiranyl-1,2-ethanediyl acetal, cyclic 3,42-an
cotylenin-a

Research Excerpts

Overview

Cotylenin A is a novel fusicoccane diterpene glycoside with a complex sugar moiety. It affected the differentiation of leukemia cells in primary culture.

ExcerptReferenceRelevance
"Cotylenin A, which is a novel fusicoccane diterpene glycoside with a complex sugar moiety, affected the differentiation of leukemia cells that were freshly isolated from acute myelogenous leukemia patients in primary culture."( Therapeutic strategy using phenotypic modulation of cancer cells by differentiation-inducing agents.
Akimoto, M; Honma, Y, 2007
)
1.06

Effects

Cotylenin A has been shown to inhibit the growth of various cancer cells. It has differentiation-inducing activity in human myeloid leukemia cell lines and leukemic cells.

ExcerptReferenceRelevance
"Cotylenin A, which has a diterpenoid tricarbocyclic skeleton, has been isolated as a plant growth regulator, has been shown to affect several physiological processes of higher plants and have differentiation-inducing activity in several myeloid leukaemia cell lines. "( Differentiation of human acute myeloid leukaemia cells in primary culture in response to cotylenin A, a plant growth regulator.
Asahi, KI; Hino, KI; Honma, Y; Sassa, T; Tomoyasu, S; Yamada, K, 2001
)
1.98
"Cotylenin A has been shown to inhibit the growth of various cancer cells."( Synergistic combination therapy with cotylenin A and vincristine in multiple myeloma models.
Adachi, K; Honma, Y; Ikejiri, F; Inoue, M; Jo, Y; Kawakami, K; Kumanomidou, S; Miyake, T; Moriyama, I; Okada, M; Onishi, C; Suzumiya, J; Takahashi, T; Takami, S; Tanaka, J, 2015
)
1.14
"Cotylenin A has been isolated as a plant growth regulator exhibits cytokinin-like activity."( Differentiation of human myeloid leukemia cells by plant redifferentiation-inducing hormones.
Honma, Y; Ishii, Y, 2002
)
1.04
"Cotylenin A has differentiation-inducing activity in human myeloid leukemia cell lines and leukemic cells that were freshly isolated from acute myeloid leukemia (AML) patients in primary culture. "( Treatment of human promyelocytic leukemia in the SCID mouse model with cotylenin A, an inducer of myelomonocytic differentiation of leukemia cells.
Asahi, K; Honma, Y; Ishii, Y; Sassa, T, 2003
)
1.99
"Cotylenin A, which has been isolated as a plant growth regulator, potently induces the differentiation of human myeloid leukemia cells. "( Cotylenin A-induced differentiation is independent of the transforming growth factor-beta signaling system in human myeloid leukemia HL-60 cells.
Honma, Y; Ishii, Y; Kasukabe, T; Matsunawa, M; Ota, H; Tomoyasu, S, 2006
)
3.22
"Cotylenin A has been isolated as a plant growth regulator."( Induction of the monocytic differentiation of myeloid leukaemia cells by cotylenin A, a plant growth regulator.
Asahi, KI; Honma, Y; Ishii, Y; Tomoyasu, S; Yamada, K; Yamamoto-Yamaguchi, Y, 2001
)
1.26
"Cotylenin A, which has a diterpenoid tricarbocyclic skeleton, has been isolated as a plant growth regulator, has been shown to affect several physiological processes of higher plants and have differentiation-inducing activity in several myeloid leukaemia cell lines. "( Differentiation of human acute myeloid leukaemia cells in primary culture in response to cotylenin A, a plant growth regulator.
Asahi, KI; Hino, KI; Honma, Y; Sassa, T; Tomoyasu, S; Yamada, K, 2001
)
1.98

Actions

ExcerptReferenceRelevance
"Cotylenin A did not activate MAPK, suggesting that cotylenin A has a different mode of action."( Induction of differentiation of myeloid leukemia cells in primary culture in response to lithocholic acid acetate, a bile acid derivative, and cooperative effects with another differentiation inducer, cotylenin A.
Akimoto, M; Honma, Y; Horie, A; Makishima, M; Taketani, T; Tsumura, H; Yamaguchi, S, 2008
)
1.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (29)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (3.45)18.2507
2000's15 (51.72)29.6817
2010's13 (44.83)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.94

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.94 (24.57)
Research Supply Index3.40 (2.92)
Research Growth Index5.75 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.94)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (13.79%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other25 (86.21%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]